Global Inflammatory Bowel Disease (IBD) Therapeutics Industry

Global Inflammatory Bowel Disease (IBD) Therapeutics Industry

  • April 2021 •
  • 216 pages •
  • Report ID: 6051219 •
  • Format: PDF
Abstract:
- Global Inflammatory Bowel Disease (IBD) Therapeutics Market to Reach $7.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Inflammatory Bowel Disease (IBD) Therapeutics estimated at US$6.8 Billion in the year 2020, is projected to reach a revised size of US$7.2 Billion by 2027, growing at a CAGR of 1% over the analysis period 2020-2027. Biologic Therapies, one of the segments analyzed in the report, is projected to record a 0.8% CAGR and reach US$4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Aminosalicylates segment is readjusted to a revised 1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 2.2% CAGR
- The Inflammatory Bowel Disease (IBD) Therapeutics market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 2.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -0.2% and 0.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.2% CAGR.
- Antibiotics Segment to Record 1.8% CAGR
- In the global Antibiotics segment, USA, Canada, Japan, China and Europe will drive the 1.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.1 Billion in the year 2020 will reach a projected size of US$1.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$936.9 Million by the year 2027, while Latin America will expand at a 2.4% CAGR through the analysis period.

- Select Competitors (Total 69 Featured) -
  • 4SC AG
  • Abbott Nutrition
  • AbbVie, Inc.
  • Ablynx NV
  • Active Biotech AB
  • Alfasigma S.p.A.
  • Allergan PLC
  • Allergan PLC
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Athersys, Inc.
  • Atlantic Healthcare plc
  • Avaxia Biologics, Inc.
  • Biosafe Systems, LLC
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Ltd.
  • Celgene Corporation
  • Celltrion, Inc.
  • Cipla Ltd.
  • Coherus Biosciences, Inc.
  • Cosmo Pharmaceuticals NV
  • Dr. Falk Pharma GmbH
  • EA Pharma Co., Ltd.
  • Eddingpharm
  • EPIRUS Biopharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • F. Hoffmann-La Roche AG
  • Galapagos NV
  • Giaconda Ltd.
  • Google LLC
  • Immunic, Inc.
  • InDex Pharmaceuticals Holding AB
  • Infinity Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Kissei Pharmaceutical Co., Ltd.
  • LG Sciences
  • Lupin Ltd.
  • Mochida Pharmaceutical Co., Ltd.
  • Mylan Pharmaceutical Pvt. Ltd.
  • Neovacs SA
  • Nogra Pharma Limited
  • NovaMedica LLC
  • Novartis International AG
  • Osiris Therapeutics, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • PAR Pharmaceutical Companies, Inc.
  • PendoPharm, Inc.
  • Perrigo Company PLC
  • Pfenex, Inc.
  • Pfizer, Inc.
  • Pharmascience Inc.
  • Pluristem Therapeutics, Inc.
  • Qu Biologics Inc.
  • Quest Diagnostics, Inc.
  • RedHill Biopharma Ltd.
  • Reliance Life Sciences
  • Salix Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi
  • Sequella, Inc.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Torrent Pharmaceuticals Ltd.
  • UCB SA
  • Zeria Pharmaceutical Co., Ltd.